China’s Wu Capital leads $91.5m Series A round in genetic firm Korro Bio

China’s Wu Capital leads $91.5m Series A round in genetic firm Korro Bio

Cambridge-based biotech startup Korro Bio has raised $91.5 million in a Series A funding round led by Chinese investment firm Wu Capital to boost its gene-editing therapies.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter